| 
								
									| Ensuring Confidentiality |  
								| 
										Maintaining 
									  registrant confidentiality was one of the primary considerations 
									  in developing the system. An advisory panel 
									  made up of representatives from patient groups, the U.S. Food and Drug Administration, and participating companies helped design 
									  the system to safeguard sensitive registrant information. To ensure 
									  confidentiality, the Patient Notification System is operated 
									  by Sedgwick, an independent 
									  organization that specializes in pharmaceutical notifications.
									All registrant information will be held in strict confidence by Sedgwick
									 |  
 
 
								
									| Free to Registrants |  
								| 
										There is no fee to participate in the Patient Notification System. The system is funded by the participating companies and is free to all registrants.
										
									 |  
 
 
								
									| Cooperative Effort Between Industry and Stakeholders |  
								|     Founding Partners:
									  
										  These stakeholders worked closely with the plasma protein therapeutics industry in designing 
									  the Patient Notification System in 1998.Alpha-1 Foundation
										  Committee of Ten Thousand
										  Hemophilia Federation of America
										  Immune Deficiency Foundation
										  National Bleeding Disorders Foundation
									   The system is administered 
									  by PPTA and is supported and funded by all participating companies. 
									                                           
										   ADMA Biologics Inc.
										   Bayer Healthcare LLC 
                                           CSL Behring
										   CSL Behring Canada
                                           Genentech, a member of the Roche Group
										   Grifols Therapeutics LLC
										   Kedrion Biopharma Inc.
										   Novo Nordisk
										   Octapharma USA Inc.
										   Octapharma Canada Inc.
										   Pfizer Inc.										   
                                           Takeda
                                        An advisory panel made up of patient groups, the FDA, and industry representatives provides input 
									  on the system and makes additional recommendations for future 
									  enhancements. |  
 
 
								
									| How the System Works |  
								| Anyone interested in participating registers with the Patient 
									  Notification System and provides general contact information, 
									  including their preferred method of notification. Registrants 
									  have the opportunity of being notified by email, telephone, text message or fax, 
									   whichever is most convenient for them. Please consider email or text message as your
									   method of notification as both are instantaneous, 
										trackable, and immediately accessible, even when away from home. 
									
									If a therapy is withdrawn or recalled, the company involved immediately 
									  contacts Sedgwick which then directly notifies the registrant. 
									   Each registrant will also receive a letter by first-class mail 
									  to ensure receipt of the information. 
									  In addition, registrants can go online to www.PatientNotificationSystem.org or call a 24-hour, 
									  toll-free number 1-888-UPDATE-U (1-888-873-2838) for current information on 
									  therapy recalls or withdrawals. To maximize the usefulness of the system, it is 
									  important for registrants to keep accurate infusion logs and record the 
									  lot number, therapy name, and manufacturer for all therapies used. |  | 
 
   
 
 The Patient Notification System is endorsed by the following patient groups:
 
                        
                            Alpha-1 FoundationGBS/CIDP FoundationHemophilia Federation of AmericaImmune Deficiency FoundationNational Bleeding Disorders Foundation 
 
						Register Today!
					 |